checkmate 214 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced

Keyword	CPC	PCC	Volume	Score	Length of keyword
checkmate 214	0.92	0.8	8826	64	13
checkmate	0.23	0.8	1002	87	9
214	0.48	0.2	4078	51	3

Keyword	CPC	PCC	Volume	Score
checkmate 214	1.71	0.9	8542	28
checkmate 214 trial	0.98	0.5	1152	31
checkmate 214 update 2023	1.68	0.4	8896	85
checkmate 214 update	0.55	0.7	3776	34
checkmate 214 nejm	0.82	0.1	4267	17
checkmate 214 clinical trial	1.17	0.9	7638	35
checkmate 214 update 2022	0.69	0.5	1558	5
checkmate 214 5 year follow up	1.32	0.7	8354	53
checkmate 214 sarcomatoid	0.92	0.6	6185	68
checkmate 214 2023	1.24	1	4390	1
checkmate 214 study	0.42	0.9	776	19
checkmate 214 sarcomatoid 2023	1.86	0.8	1547	56
checkmate 214 5 year	1.08	0.4	9820	5

Search Results related to checkmate 214 on Search Engine

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1712126

WEBMar 21, 2018 · (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .) Quick Take. Sunitinib or Nivolumab plus Ipilimumab for Renal-Cell Carcinoma. 2m 12s.

DA: 18 PA: 33 MOZ Rank: 62

Nivolumab plus ipilimumab versus sunitinib for first-line ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33246931/

WEBAbstract. Purpose: To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC).

DA: 71 PA: 11 MOZ Rank: 26

Nivolumab plus ipilimumab versus sunitinib for first-line treatment …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703447/

WEBNov 27, 2020 · To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC).

DA: 98 PA: 96 MOZ Rank: 11

Nivolumab Combined With Ipilimumab Versus Sunitinib in …
clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT02231749

WEBSep 4, 2014 · First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol. 2022 Mar;81(3):266-271. doi: 10.1016/j.eururo.2021.10.001. Epub 2021 Nov 5.

DA: 100 PA: 22 MOZ Rank: 87

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.363

WEBJanuary 29, 2024. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial. Authors: Nizar M. Tannir, Bernard Escudier, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Elizabeth R. Plimack, …

DA: 73 PA: 61 MOZ Rank: 80

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients
nih.gov

https://pubmed.ncbi.nlm.nih.gov/34750035/

WEBWe present an exploratory post hoc analysis from the phase 3 CheckMate 214 trial of first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib in a subgroup of 108 patients with advanced renal cell carcinoma (aRCC) without prior nephrectomy and with an evaluable primary tumor, a population under-represented in clinical trials.

DA: 38 PA: 99 MOZ Rank: 100

Nivolumab plus ipilimumab versus sunitinib in first-line treatment …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497870/

WEBIn the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (NIVO+IPI) demonstrated superior efficacy over sunitinib (SUN) in patients with previously untreated IMDC intermediate/poor-risk advanced renal cell …

DA: 96 PA: 66 MOZ Rank: 75

Efficacy and Safety of Nivolumab Plus Ipilimumab versus …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589223/

WEBJan 1, 2021 · Here, we present post hoc exploratory analyses in the subpopulation of patients with sRCC in the phase III CheckMate 214 trial, which demonstrated sustained superiority of first-line dual checkpoint inhibition with NIVO+IPI versus sunitinib (SUN) in patients with advanced RCC (aRCC).

DA: 68 PA: 77 MOZ Rank: 82

CheckMate 214: A phase III, randomized, open-label study of …
ascopubs.org

https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.tps4578

WEBMay 20, 2015 · CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. | Journal of Clinical Oncology. Free access. Genitourinary (Nonprostate) Cancer. May 20, 2015.

DA: 13 PA: 49 MOZ Rank: 84

Efficacy and safety of nivolumab plus ipilimumab (N+I) versus …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.352

WEBFeb 16, 2022 · Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. | Journal of Clinical Oncology. Free access. Renal Cell Cancer. February 16, 2022.

DA: 29 PA: 23 MOZ Rank: 83